News
09-02-2010, 10:50 PM
Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer".
More... (http://www.news-medical.net/news/20100903/Celsion-receives-NIH-SBIR-grant-to-develop-heat-sensitive-liposomal-technology-for-cancer-treatment.aspx)
More... (http://www.news-medical.net/news/20100903/Celsion-receives-NIH-SBIR-grant-to-develop-heat-sensitive-liposomal-technology-for-cancer-treatment.aspx)